Oryzon Genomics SA

Oryzon Genomics SA is a clinical stage biopharmaceutical company and the European leader in the development of epigenetics-based therapeutics, with a strong focus on personalized medicine approaches to CNS disorders and oncology. The company's portfolio includes iadademstat, a highly potent and selective LSD1 inhibitor, in Phase IIa clinical trials for the treatment of acute myeloid leukemia and small cell lung cancer, and vafidemstat, a CNS optimized LSD1 inhibitor in multiple Phase II trials for the treatment of CNS and psychiatric diseases. Oryzon also has a strong technological platform for biomarker identification and performs biomarker and target validation for a variety of malignant and neurological diseases. Since its foundation in 2000, Oryzon has been listed on the Spanish Stock Exchange. The company has attracted specialized investors from US, Israel, and Europe in several PIPEs led by different US investment banks. Their most recent investment of $498.69K came in the form of a grant from The ALS Association on 04 December 2023. Oryzon continues to expand its presence with offices in Spain and the United States. With its innovative approach to personalized medicine in epigenetics, Oryzon Genomics stands as a promising player in the Biopharma, Biotechnology, and Health Care industries.